Apiam Animal Health Limited, a vertically integrated animal health company, provides veterinary products and services to production and companion animals in Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.94|
|52 Week High||AU$0.57|
|52 Week Low||AU$1.00|
|1 Month Change||-3.59%|
|3 Month Change||-2.08%|
|1 Year Change||28.77%|
|3 Year Change||69.37%|
|5 Year Change||-32.86%|
|Change since IPO||-25.40%|
Recent News & Updates
Apiam Animal Health (ASX:AHX) Has Announced A Dividend Of AU$0.012
The board of Apiam Animal Health Limited ( ASX:AHX ) has announced that it will pay a dividend of AU$0.012 per share on...
Apiam Animal Health (ASX:AHX) Has Re-Affirmed Its Dividend Of AU$0.012
Apiam Animal Health Limited ( ASX:AHX ) will pay a dividend of AU$0.012 on the 22nd of October. This means the dividend...
|AHX||AU Healthcare||AU Market|
Return vs Industry: AHX exceeded the Australian Healthcare industry which returned 14.2% over the past year.
Return vs Market: AHX exceeded the Australian Market which returned 21.3% over the past year.
Stable Share Price: AHX is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: AHX's weekly volatility (5%) has been stable over the past year.
About the Company
Apiam Animal Health Limited, a vertically integrated animal health company, provides veterinary products and services to production and companion animals in Australia. The company operates through three segments: Dairy and Mixed, Feedlots, and Pigs. It engages in the provision of veterinary wholesale, diagnostics laboratories, custom vaccines, logistics, and other ancillary services.
Apiam Animal Health Fundamentals Summary
|AHX fundamental statistics|
Is AHX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AHX income statement (TTM)|
|Cost of Revenue||AU$100.87m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.037|
|Net Profit Margin||4.03%|
How did AHX perform over the long term?See historical performance and comparison
2.6%Current Dividend Yield
Is Apiam Animal Health undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AHX (A$0.94) is trading below our estimate of fair value (A$7.07)
Significantly Below Fair Value: AHX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AHX's PE Ratio (25.1x) is in line with the Australian Healthcare industry average.
PE vs Market: AHX is poor value based on its PE Ratio (25.1x) compared to the Australian market (19.9x).
Price to Earnings Growth Ratio
PEG Ratio: AHX is poor value based on its PEG Ratio (1x)
Price to Book Ratio
PB vs Industry: AHX is good value based on its PB Ratio (1.6x) compared to the AU Healthcare industry average (2.1x).
How is Apiam Animal Health forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AHX's forecast earnings growth (25.1% per year) is above the savings rate (1.9%).
Earnings vs Market: AHX's earnings (25.1% per year) are forecast to grow faster than the Australian market (11.5% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: AHX's revenue (8.3% per year) is forecast to grow faster than the Australian market (5.5% per year).
High Growth Revenue: AHX's revenue (8.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AHX's Return on Equity is forecast to be low in 3 years time (12.3%).
How has Apiam Animal Health performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AHX has high quality earnings.
Growing Profit Margin: AHX's current net profit margins (4%) are higher than last year (3.5%).
Past Earnings Growth Analysis
Earnings Trend: AHX's earnings have grown by 8.1% per year over the past 5 years.
Accelerating Growth: AHX's earnings growth over the past year (24.1%) exceeds its 5-year average (8.1% per year).
Earnings vs Industry: AHX earnings growth over the past year (24.1%) underperformed the Healthcare industry 61.3%.
Return on Equity
High ROE: AHX's Return on Equity (6.2%) is considered low.
How is Apiam Animal Health's financial position?
Financial Position Analysis
Short Term Liabilities: AHX's short term assets (A$33.3M) exceed its short term liabilities (A$24.4M).
Long Term Liabilities: AHX's short term assets (A$33.3M) do not cover its long term liabilities (A$51.4M).
Debt to Equity History and Analysis
Debt Level: AHX's debt to equity ratio (46.6%) is considered high.
Reducing Debt: AHX's debt to equity ratio has increased from 33.6% to 46.6% over the past 5 years.
Debt Coverage: AHX's debt is well covered by operating cash flow (36.3%).
Interest Coverage: AHX's interest payments on its debt are well covered by EBIT (7x coverage).
What is Apiam Animal Health current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: AHX's dividend (2.55%) is higher than the bottom 25% of dividend payers in the Australian market (2.23%).
High Dividend: AHX's dividend (2.55%) is low compared to the top 25% of dividend payers in the Australian market (5.3%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, AHX has been paying a dividend for less than 10 years.
Growing Dividend: AHX's dividend payments have increased, but the company has only paid a dividend for 5 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (56.9%), AHX's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: AHX's dividends in 3 years are forecast to be well covered by earnings (40% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Christopher Irwin Richards, also known as Chris, BSc, BVSc, MAICD, has been Managing Director of Apiam Animal Health Limited since November 1, 2015. Dr. Richards founded Chris Richards & Associates in...
CEO Compensation Analysis
Compensation vs Market: Chris's total compensation ($USD340.14K) is about average for companies of similar size in the Australian market ($USD302.87K).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
Experienced Management: AHX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: AHX's board of directors are considered experienced (5.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: AHX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.3%.
Apiam Animal Health Limited's employee growth, exchange listings and data sources
- Name: Apiam Animal Health Limited
- Ticker: AHX
- Exchange: ASX
- Founded: 1998
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: AU$127.449m
- Shares outstanding: 135.58m
- Website: https://www.apiam.com.au
Number of Employees
- Apiam Animal Health Limited
- 27-33 Piper Lane
- East Bendigo
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/24 07:01|
|End of Day Share Price||2021/10/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.